359 related articles for article (PubMed ID: 17549932)
41. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
42. Compensating Pharmaceutical Injuries in the Absence of Fault.
Rowin MA
Food Drug Law J; 2014; 69(3):447-70, ii. PubMed ID: 27382858
[TBL] [Abstract][Full Text] [Related]
43. Legal preparedness for bioterrorism.
Matthews GW; Benjamin G; Mills SP; Parmet W; Misrahi JJ
J Law Med Ethics; 2002; 30(3 Suppl):52-6. PubMed ID: 12508503
[TBL] [Abstract][Full Text] [Related]
44. Proposal 4 is only right.
Knoll K
Mich Health Hosp; 2002; 38(6):28-30. PubMed ID: 12402652
[No Abstract] [Full Text] [Related]
45. Biodefense: spend, but spend wisely.
Green SK; Morin K
Am J Bioeth; 2005; 5(4):50-2. PubMed ID: 16109698
[No Abstract] [Full Text] [Related]
46. [Reasons for an injury compensation programme for adverse vaccine-related events in Spain].
Tuells J
Med Clin (Barc); 2013 Jun; 140(12):554-7. PubMed ID: 23540383
[No Abstract] [Full Text] [Related]
47. Administrative "health courts" for medical injury claims: the federal constitutional issues.
Elliott ED; Narayan SA; Nasmith MS
J Health Polit Policy Law; 2008 Aug; 33(4):761-98. PubMed ID: 18617674
[TBL] [Abstract][Full Text] [Related]
48. On economic justifications of bioterrorism defense spending.
Allhoff F
Am J Bioeth; 2005; 5(4):52-4. PubMed ID: 16109699
[No Abstract] [Full Text] [Related]
49. [The strategic plan for preparedness and response to bioterrorism in Korea].
Hwang HS
J Prev Med Public Health; 2008 Jul; 41(4):209-13. PubMed ID: 18664725
[TBL] [Abstract][Full Text] [Related]
50. Bioterrorism, public health, and the law.
Bayer R; Colgrove J
Health Aff (Millwood); 2002; 21(6):98-101. PubMed ID: 12442844
[TBL] [Abstract][Full Text] [Related]
51. Emergency legal preparedness for hospitals and health care personnel.
Hodge JG; Garcia AM; Anderson ED; Kaufman T
Disaster Med Public Health Prep; 2009 Jun; 3(2 Suppl):S37-44. PubMed ID: 19491586
[TBL] [Abstract][Full Text] [Related]
52. Update on the National Vaccine Injury Compensation Program.
Edlich RF; Olson DM; Olson BM; Greene JA; Gubler KD; Winters KL; Kelley AR; Britt LD; Long WB
J Emerg Med; 2007 Aug; 33(2):199-211. PubMed ID: 17692778
[TBL] [Abstract][Full Text] [Related]
53. The Smallpox Vaccine Injury Compensation Program.
Clark PT; Levin S
Clin Infect Dis; 2008 Mar; 46 Suppl 3():S179-81. PubMed ID: 18284357
[TBL] [Abstract][Full Text] [Related]
54. Bioterrorism defense education: prioritizing public health education.
Egan EA
Am J Bioeth; 2005; 5(4):47-8. PubMed ID: 16109696
[No Abstract] [Full Text] [Related]
55. End the stalemate on tort reform. Senate still a barrier to lower costs, better availability of malpractice insurance.
Raske K
Mod Healthc; 2005 Aug; 35(33):34. PubMed ID: 16124733
[No Abstract] [Full Text] [Related]
56. Democratic defense spending in an age of bioterrorism.
Selgelid MJ
Am J Bioeth; 2005; 5(4):49-50. PubMed ID: 16109697
[No Abstract] [Full Text] [Related]
57. "Insuring" the continued solvency of pharmaceutical companies in the face of product liability class actions.
Chodock R; Yolkut D; Connolly DR
Tort Trial Insur Pract Law J; 2005; 40(3):997-1017. PubMed ID: 16100814
[TBL] [Abstract][Full Text] [Related]
58. Preparedness on the frontline: what's law got to do with it?
Lichtveld M; Hodge JG; Gebbie K; Thompson FE; Loos DI
J Law Med Ethics; 2002; 30(3 Suppl):184-8. PubMed ID: 12508524
[TBL] [Abstract][Full Text] [Related]
59. Who will pay for the adverse events resulting from smallpox vaccination? Liability and compensation issues.
Strongin RJ; Salinsky E
NHPF Issue Brief; 2003 Mar; (788):1-15. PubMed ID: 12650125
[TBL] [Abstract][Full Text] [Related]
60. Public health law in the new century.
Reynolds C
J Law Med; 2003 May; 10(4):435-41. PubMed ID: 12852317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
